Nephrogen Analysis: $125K Raised
What is Nephrogen?
Nephrogen is a preclinical biotech company and Stanford spinout developing curative genomic medicines. It commercializes a platform called NeFIND for AI and high-throughput in vivo screening of tissue-specific delivery vehicles. The site highlights kidney and pancreas applications, including polycystic kidney disease and ADPKD.
Location
100 Cummings Center, Beverly, Massachusetts, 01915, US
Employees
1-10
Founded
2022
Revenue
$5M
Product Features & Capabilities
- curative gene therapies for kidney diseases, targeting autosomal dominant polycystic kidney disease (ADPKD), non-invasive local delivery method, engineered AAV viruses with 100x better efficiency, personalized approach targeting PKD1 gene, rapid drug discovery platform leveraging computer vision and high-throughput screening
How much Nephrogen raised
1: - $125K
January 1, 2020Lead Investor: Not specified
Competitors Overview
Nephrogen operates in the gene therapy market for kidney diseases, particularly focusing on autosomal dominant polycystic kidney disease (ADPKD). Its main competitors include:
-
Otsuka Pharmaceutical Co., Ltd.: Known for its drug tolvaptan, which is approved for the treatment of ADPKD. Otsuka has a strong market presence and established products, giving it a competitive edge in terms of experience and regulatory approval.
-
AbbVie Inc.: This company is involved in various therapeutic areas, including kidney diseases. AbbVie has a robust pipeline and significant resources for research and development, which may provide advantages in innovation and market reach.
-
Sanofi: A major player in the pharmaceutical industry, Sanofi is also exploring treatments for kidney diseases. Its extensive experience and global distribution network can be advantageous in bringing new therapies to market.
-
Reata Pharmaceuticals: Focused on developing therapies for serious diseases, including kidney conditions. Reata's innovative approach and targeted therapies may offer unique benefits compared to traditional treatments.
-
Galapagos NV: This biotech company is involved in developing therapies for various diseases, including kidney-related conditions. Their focus on novel mechanisms of action may differentiate them in the market.
-
Janssen Pharmaceuticals: A subsidiary of Johnson & Johnson, Janssen has a strong portfolio in various therapeutic areas, including nephrology. Their extensive resources and research capabilities provide a competitive advantage.
These competitors have established products, significant research capabilities, and market experience, which may present challenges for Nephrogen as it seeks to develop and commercialize its gene therapies.
Market Focus
Nephrogen primarily focuses on the biotechnology industry, specifically developing curative gene therapies for life-threatening kidney diseases, with an emphasis on autosomal dominant polycystic kidney disease (ADPKD).
Investors
- 2048 Ventures
- Contrary (San Francisco)
- Darwin (Munich)
- Lightspeed Venture Partners
- Phoenix Investment Club (San Francisco)
- StartX (Stanford-StartX Fund)
- Y Combinator
See something that needs updating? Suggest edits to this profile.